The oncosuppressor miR-137 targets alanine, serine, cysteine, and glutamate transporter (ASCT2), negatively correlated with ASCT2 in pancreatic ductal adenocarcinoma, pancreatic cancer, glioblastoma, and CRC (134). This evidence concerns the gene SLC1A5 and colorectal carcinoma.